News
-
The FDA issued a warning letter to AstraZeneca dated August 4, 2023 that cites multiple “false or misleading claims and/or representations” about the efficacy of the company’s Breztri Aerosphere (PT010) budesonide / glycopyrrolate / formoterol fumarate… Read more . . .
-
Lupin has launched its generic version of Spiriva HandiHaler tiotropium bromide DPI for the treatment of COPD in the US, the company said. The FDA approved Lupin’s ANDA for the tiotropium bromide inhaler in June… Read more . . .
-
Trudhesa dihydroergotamine (DHE) nasal spray maker Impel Pharmaceuticals (formerly Impel Neuropharma) has filed a document with the US Securities and Exchange Commission stating that it “has concluded that there is substantial doubt about the Company’s… Read more . . .
-
Galecto has announced that the Phase 2b GALACTIC-1 of its GB0139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis failed to meet its primary endpoint and, as a result, the company will discontinue… Read more . . .
-
According to Tiziana Life Sciences, the FDA has cleared the company’s IND to allow clinical development of intranasal foralumab in Alzheimer’s disease. Earlier this year, Tiziana announced plans to develop foralumab, an intranasal anti-CD3 monoclonal antibody,… Read more . . .
-
Posted on OINDPnews on August 16, 2023 University: Texas State University College of Health Professions Description:The Aerosol Medicine Research Laboratory at the Department of Respiratory Care seeks a motivated Postdoctoral Research Fellow to join our team. Aspiring… Read more . . .
-
Marinomed Biotech has announced that its Solv4U unit is working with SPH Sine Pharmaceutical Laboratories to develop an OINDP formulation using Marinomed’s Marinosolv solubility enhancement technology. According to Marinomed, a feasibility study has been completed,… Read more . . .
-
Silo Pharma said that it is planning to develop an intranasal formulation of its SPC-15, which includes “ketamine compositions,” for the prevention and treatment of stress disorders, including anxiety and PTSD. The formulation was developed… Read more . . .
-
Avalyn Pharma, which is developing inhaled formulations of pirfenidone and nintedanib for the treatment of pulmonary fibrosis, has announced the appointment of former Altavant Sciences Chief Medical Officer Howard M. Lazarus as Chief Medical Officer. Lazarus’s… Read more . . .
-
Vistagen has announced that the Phase 3 PALISADE-2 public speaking challenge trial of PH94B fasedienol nasal spray in subjects with social anxiety disorder met its primary and secondary endpoints. The company announced the initiation of… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan